The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Liposomal siRNA nanocarriers for cancer therapy
Open accessAbstract
Small interfering RNAs (siRNA) have recently emerged as a new class of therapeutics with a great potential to revolutionize the treatment of cancer and other diseases. A specifically designed siRNA binds and induces post-transcriptional silencing of target genes (mRNA). Clinical applications of siRNA-based therapeutics have been limited by their rapid degradation, poor cellular uptake, and rapid renal clearance following systemic administration. A variety of synthetic and natural nanoparticles composed of lipids, polymers, and metals have been developed for siRNA delivery, with different efficacy and safety profiles. Liposomal nanoparticles have proven effective in delivering siRNA into tumor tissues by improving stability and bioavailability. While providing high transfection efficiency and a capacity to form complexes with negatively charged siRNA, cationic lipids/liposomes are highly toxic. Negatively charged liposomes, on the other hand, are rapidly cleared from circulation. To overcome these problems we developed highly safe and effective neutral lipid-based nanoliposomes that provide robust gene silencing in tumors following systemic (intravenous) administration. This delivery system demonstrated remarkable antitumor efficacy in various orthotopic human cancer models in animals. Here, we briefly overview this and other lipid-based approaches with preclinical applications in different tumor models for cancer therapy and potential applications as siRNA-nanotherapeutics in human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells
Hammond, S. M., Bernstein, E., Beach, D., & Hannon, G. J. (2000) · Nature · doi:10.1038/35005107 · Cited by 3,003
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,150
Jackson, A. L., & Linsley, P. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3010 · Cited by 1,083
Unlocking the potential of the human genome with RNA interference
Hannon, G. J., & Rossi, J. J. (2004) · Nature · doi:10.1038/nature02870 · Cited by 1,064
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs
Wolfrum, C., Shi, S., Jayaprakash, K. N., Jayaraman, M., Wang, G., Pandey, R. K., Rajeev, K. G., Nakayama, T., Charrise, K., Ndungo, E. M., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1339 · Cited by 974
RNA-Based Therapeutics: Current Progress and Future Prospects
Burnett, J. C., & Rossi, J. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.008 · Cited by 819
Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer
Merritt, W. M., Lin, Y. G., Han, L. Y., Kamat, A. A., Spannuth, W. A., Schmandt, R., Urbauer, D., Pennacchio, L. A., Cheng, J.-F., Nick, A. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803785 · Cited by 712
Self-citationTabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Landen, C. N., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., & Sood, A. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0530 · Cited by 675
Self-citationGreish, K. (2007) · Journal of Drug Targeting · doi:10.1080/10611860701539584 · Cited by 600
Kedmi, R., Ben-Arie, N., & Peer, D. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.05.027 · Cited by 546
Miller, C. R., Bondurant, B., McLean, S. D., McGovern, K. A., & O'Brien, D. F. (1998) · Biochemistry · doi:10.1021/bi980096y · Cited by 524
Folate receptor alpha as a tumor target in epithelial ovarian cancer
Kalli, K. R., Oberg, A. L., Keeney, G. L., Christianson, T. J. H., Low, P. S., Knutson, K. L., & Hartmann, L. C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.020 · Cited by 475
Filion, M. C., & Phillips, N. C. (1997) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(97)00126-0 · Cited by 428
Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382
Lee, J., Lee, K., Moon, S. H., Lee, Y., Park, T. G., & Cheon, J. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200805998 · Cited by 365
Oxygen Radical-Mediated Pulmonary Toxicity Induced by Some Cationic Liposomes
Dokka, S., Toledo, D., Shi, X., Castranova, V., & Rojanasakul, Y. (2000) · Pharmaceutical Research · doi:10.1023/a:1007504613351 · Cited by 349
Spagnou, S., Miller, A. D., & Keller, M. (2004) · Biochemistry · doi:10.1021/bi048950a · Cited by 342
Minakuchi, Y. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh093 · Cited by 336
Halder, J., Kamat, A. A., Landen, C. N., Han, L. Y., Lutgendorf, S. K., Lin, Y. G., Merritt, W. M., Jennings, N. B., Chavez-Reyes, A., Coleman, R. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0021 · Cited by 297
Self-citationQuantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference
Tan, W. B., Jiang, S., & Zhang, Y. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.11.018 · Cited by 295
Development of anti-p185HER2 immunoliposomes for cancer therapy.
Park, J. W., Hong, K., Carter, P., Asgari, H., Guo, L. Y., Keller, G. A., Wirth, C., Shalaby, R., Kotts, C., & Wood, W. I. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1327 · Cited by 258
Merritt, W. M., Lin, Y. G., Spannuth, W. A., Fletcher, M. S., Kamat, A. A., Han, L. Y., Landen, C. N., Jennings, N., De Geest, K., Langley, R. R., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn024 · Cited by 257
Self-citationNanomedicine based approaches for the delivery of siRNA in cancer
Ozpolat, B., Sood, A. K., & Lopez‐Berestein, G. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02191.x · Cited by 218
Self-citationNanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
Zhou, J., Shum, K.-T., Burnett, J., & Rossi, J. (2013) · Pharmaceuticals · doi:10.3390/ph6010085 · Cited by 205
Villares, G. J., Zigler, M., Wang, H., Melnikova, V. O., Wu, H., Friedman, R., Leslie, M. C., Vivas-Mejia, P. E., Lopez-Berestein, G., Sood, A. K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2397 · Cited by 163
Self-citationTherapeutic Targeting of Neuropilin-2 on Colorectal Carcinoma Cells Implanted in the Murine Liver
Gray, M. J., Van Buren, G., Dallas, N. A., Xia, L., Wang, X., Yang, A. D., Somcio, R. J., Lin, Y. G., Lim, S., Fan, F., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm279 · Cited by 158
Self-citationMajor limitations in the use of cationic liposomes for DNA delivery
Filion, M. C., & Phillips, N. C. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(97)00423-7 · Cited by 155
Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA
Fattal, E., & Bochot, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.020 · Cited by 152
Anabousi, S., Bakowsky, U., Schneider, M., Huwer, H., Lehr, C., & Ehrhardt, C. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.07.004 · Cited by 141
Kim, H. R., Kim, I. K., Bae, K. H., Hyeon, L. S., Lee, Y., & Park, T. G. (2008) · Molecular Pharmaceutics · doi:10.1021/mp8000233 · Cited by 139
Transferrin-Conjugated Liposome Targeting of Photosensitizer AlPcS4 to Rat Bladder Carcinoma Cells
Derycke, A., Kamuhabwa, A. A. R., Gijsens, A., Roskams, T., Vos, D. E. D., Kasran, A., Huwyler, J., Missiaen, L., & de Witte, P. A. M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh314 · Cited by 135
Kim, S. H., Mok, H., Jeong, J. H., Kim, S. W., & Park, T. G. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050289f · Cited by 129
Pan, X., Arumugam, T., Yamamoto, T., Levin, P. A., Ramachandran, V., Ji, B., Lopez‐Berestein, G., Vivas‐Mejía, P. E., Sood, A. K., McConkey, D. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1539 · Cited by 129
Self-citationYu, D., Peng, P., Dharap, S. S., Wang, Y., Mehlig, M., Chandna, P., Zhao, H., Filpula, D. R., Yang, K., Borowski, V., et al. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.050 · Cited by 116
Tekedereli, İ., Alpay, S. N., Akar, U., Yuca, E., Ayugo-Rodriguez, C., Han, H.-D., Sood, A. K., Lopez‐Berestein, G., & Özpolat, B. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.45 · Cited by 106
Self-citationTucker, B. A., Redenti, S., Jiang, C., Swift, J. S., Klassen, H. J., Smith, M., Wnek, G. E., & Young, M. J. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.09.015 · Cited by 105
Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts
Yoshizawa, T., Hattori, Y., Hakoshima, M., Koga, K., & Maitani, Y. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.06.026 · Cited by 99
Surface Modification of RGD-Liposomes for Selective Drug Delivery to Monocytes/Neutrophils in Brain
Qin, J., Chen, D., Hu, H., Cui, Q., Qiao, M., & Chen, B. (2007) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.55.1192 · Cited by 66
Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene Using Liposomal Nanovectors
Shao, L., Tekedereli, İ., Wang, J., Yuca, E., Tsang, S. V., Sood, A. K., Lopez‐Berestein, G., Özpolat, B., & Ittmann, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2715 · Cited by 62
Self-citationSuzuki, S., Inoue, K., Hongoh, A., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.340 · Cited by 50
Silencing of p130Cas in Ovarian Carcinoma: A Novel Mechanism for Tumor Cell Death
Nick, A. M., Stone, R. L., Armaiz-Peña, G. N., Özpolat, B., Tekedereli, İ., Graybill, W. A. S., Landen, C. N., Villares, G. J., Vivas‐Mejía, P. E., Bottsford-Miller, J. N., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr372 · Cited by 50
Self-citationFolate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy.
Stephenson, S. M., Yang, W., Stevens, P. J., Tjarks, W., Barth, R. F., & Lee, R. J. (2003) · PubMed · Cited by 42
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Nanostructured lipid carriers: Promising drug delivery systems for future clinics
Beloqui, A., Solinís, M. Á., Rodríguez-Gascón, A., Almeida, A. J., & Préat, V. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.09.004 · Cited by 769
Johnsen, K. B., Gudbergsson, J. M., Skov, M. N., Pilgaard, L., Moos, T., & Duroux, M. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.005 · Cited by 704
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 626
Metadata
- Authors
- Ozpolat, B., Sood, A. K., & Lopez-Berestein, G.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 66
- Pages
- 110-116
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2125460615
- Cited by
- 442
- References
- 51
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.